

P&T Motion History
Calcitonin Gene-Related Peptide Inhibitors (CGRP)

Drugs reviewed	Motion	Date reviewed	Surveillance accepted as adequate	Reiteration of prior motion	Decision
eptinezumab erenumab fremanezumab galcanezumab rimegepant ubrogepant	<p>After considering the evidence of safety and efficacy for the treatment of migraine prophylaxis, I move that eptinezumab, erenumab, fremanezumab, galcanezumab are safe and efficacious for the treatment of their approved indications. These CGRP Inhibitors should be second line agents on the Washington PDL. Erenumab, eptinezumab, fremanezumab, and galcanezumab can be subject to therapeutic interchange in the Washington preferred drug list.</p> <p>After considering the evidence of safety and efficacy for the treatment of acute migraine, I move that rimegepant and ubrogepant are safe and efficacious for the treatment of their approved indications as second line agents on the Washington PDL. Rimegepant and ubrogepant can be subject to therapeutic interchange with each other in the Washington preferred drug list.</p> <p>Provide an updated class review.</p>	October 19, 2022	Yes Park MacKay	Yes Park Marcotte	Passed unanimous

Bold = new this update
 Grey = not FDA approved
10/20/2022